JP2022544836A - Ｍ２マクロファージおよび骨髄系由来サプレッサー細胞を除去するための組成物ならびに関連する方法 - Google Patents

Ｍ２マクロファージおよび骨髄系由来サプレッサー細胞を除去するための組成物ならびに関連する方法 Download PDF

Info

Publication number
JP2022544836A
JP2022544836A JP2022511023A JP2022511023A JP2022544836A JP 2022544836 A JP2022544836 A JP 2022544836A JP 2022511023 A JP2022511023 A JP 2022511023A JP 2022511023 A JP2022511023 A JP 2022511023A JP 2022544836 A JP2022544836 A JP 2022544836A
Authority
JP
Japan
Prior art keywords
compound
independently
mannose
therapeutic agent
macrophages
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022511023A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544836A5 (https=
Inventor
ラルフ、デイビッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Navidea Biopharmaceuticals Inc
Original Assignee
Navidea Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navidea Biopharmaceuticals Inc filed Critical Navidea Biopharmaceuticals Inc
Publication of JP2022544836A publication Critical patent/JP2022544836A/ja
Publication of JP2022544836A5 publication Critical patent/JP2022544836A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2022511023A 2019-08-19 2020-08-19 Ｍ２マクロファージおよび骨髄系由来サプレッサー細胞を除去するための組成物ならびに関連する方法 Pending JP2022544836A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962888727P 2019-08-19 2019-08-19
US62/888,727 2019-08-19
PCT/US2020/047036 WO2021034953A1 (en) 2019-08-19 2020-08-19 Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells

Publications (2)

Publication Number Publication Date
JP2022544836A true JP2022544836A (ja) 2022-10-21
JP2022544836A5 JP2022544836A5 (https=) 2023-08-22

Family

ID=74647058

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022511023A Pending JP2022544836A (ja) 2019-08-19 2020-08-19 Ｍ２マクロファージおよび骨髄系由来サプレッサー細胞を除去するための組成物ならびに関連する方法

Country Status (7)

Country Link
US (1) US20210052639A1 (https=)
EP (1) EP4017546A4 (https=)
JP (1) JP2022544836A (https=)
CN (1) CN114555131A (https=)
CA (1) CA3151519A1 (https=)
IL (1) IL290593A (https=)
WO (1) WO2021034953A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021019187A2 (pt) * 2019-03-27 2021-12-21 Navidea Biopharmaceuticals Inc Método para repolarização de um macrófago associado a tumor de m2 a m1, e, composto para repolarização de um macrófago associado a tumor de m2 a m1
CA3192041A1 (en) * 2020-08-21 2022-02-24 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages
WO2025096664A1 (en) * 2023-10-31 2025-05-08 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional cd206-binding molecules and methods of use

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008531755A (ja) * 2005-01-05 2008-08-14 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム 二重画像化および放射線化学療法のためのコンジュゲート：組成物、製造および適応
JP2010006768A (ja) * 2008-06-28 2010-01-14 Kanagawa Acad Of Sci & Technol 高分子ミセル及びそれを有効成分として含有する固形がんの診断又は治療剤
JP2016527252A (ja) * 2013-07-22 2016-09-08 ナビディア・バイオファーマシューティカルズ，インコーポレーテッド Ｃｄ２０６発現細胞関連障害を診断および処置するための組成物、方法およびキット
JP2017528585A (ja) * 2014-07-17 2017-09-28 オハイオ ステート イノベーション ファウンデーション マクロファージおよび他のマンノース結合ｃ型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法
US20180099048A1 (en) * 2016-10-07 2018-04-12 Navidea Biopharmaceuticals, Inc. Compounds and compositions for treating leishmaniasis and methods of diagnosis and treating using same
WO2019018815A1 (en) * 2017-07-21 2019-01-24 Navidea Biopharmaceuticals, Inc. USE OF 99MTC-TILMANOCEPT AND ASSOCIATED MOLECULAR CONSTRUCTS FOR THE IDENTIFICATION AND DIAGNOSIS OF MALIGNANT TUMORS, AND FOR THE MONITORING OF ANTI-TUMOR THERAPEUTIC INTERVENTIONS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1178838B1 (en) * 1999-05-14 2004-09-29 The Regents of the University of California Macromolecular carrier based on dextran for drug and diagnostic agent delivery
WO2016118188A1 (en) * 2015-01-21 2016-07-28 Navidea Biopharmaceuticals, Inc. Compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells
BR112021019187A2 (pt) * 2019-03-27 2021-12-21 Navidea Biopharmaceuticals Inc Método para repolarização de um macrófago associado a tumor de m2 a m1, e, composto para repolarização de um macrófago associado a tumor de m2 a m1

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008531755A (ja) * 2005-01-05 2008-08-14 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム 二重画像化および放射線化学療法のためのコンジュゲート：組成物、製造および適応
JP2010006768A (ja) * 2008-06-28 2010-01-14 Kanagawa Acad Of Sci & Technol 高分子ミセル及びそれを有効成分として含有する固形がんの診断又は治療剤
JP2016527252A (ja) * 2013-07-22 2016-09-08 ナビディア・バイオファーマシューティカルズ，インコーポレーテッド Ｃｄ２０６発現細胞関連障害を診断および処置するための組成物、方法およびキット
JP2017528585A (ja) * 2014-07-17 2017-09-28 オハイオ ステート イノベーション ファウンデーション マクロファージおよび他のマンノース結合ｃ型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法
US20180099048A1 (en) * 2016-10-07 2018-04-12 Navidea Biopharmaceuticals, Inc. Compounds and compositions for treating leishmaniasis and methods of diagnosis and treating using same
WO2019018815A1 (en) * 2017-07-21 2019-01-24 Navidea Biopharmaceuticals, Inc. USE OF 99MTC-TILMANOCEPT AND ASSOCIATED MOLECULAR CONSTRUCTS FOR THE IDENTIFICATION AND DIAGNOSIS OF MALIGNANT TUMORS, AND FOR THE MONITORING OF ANTI-TUMOR THERAPEUTIC INTERVENTIONS

Also Published As

Publication number Publication date
EP4017546A4 (en) 2023-09-27
WO2021034953A1 (en) 2021-02-25
EP4017546A1 (en) 2022-06-29
IL290593A (en) 2022-04-01
US20210052639A1 (en) 2021-02-25
CA3151519A1 (en) 2021-02-25
CN114555131A (zh) 2022-05-27

Similar Documents

Publication Publication Date Title
JP7665206B2 (ja) マクロファージの表現型を改変するための組成物および方法
US10398714B2 (en) Compositions and methods for inhibiting arginase activity
CN108348492B (zh) 使用谷氨酰胺类似物的用于癌症和免疫疗法的方法
JP2022544836A (ja) Ｍ２マクロファージおよび骨髄系由来サプレッサー細胞を除去するための組成物ならびに関連する方法
JP7599727B2 (ja) マンノシル化デキストラン治療用または診断用化合物の標的特異性を高めるためのキット
RU2734930C2 (ru) Режимы дозирования мелфлуфена для раковых заболеваний
JP2014524910A (ja) 癌治療のための組成物および方法
JP2024147816A (ja) がん治療における免疫モジュレーションのための組合せ
TW201642850A (zh) 透明質酸奈米顆粒在製備治療於一個體中之淋巴系統中之腫瘤之藥物的用途
US20100173865A1 (en) Anti-Cancer Agent-Hyaluronic Acid Conjugate Compositions and Methods
US12178829B2 (en) Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking
EP3760222A1 (en) Compositions and methods for inducing apoptosis
US20230302041A1 (en) Competitive Self-Blocking with Unlabeled Manocept Imaging Agents
CA2608463C (en) Compounds, compositions containing such compounds, and methods of treatment of metastatic melanoma and other cancers
US10383943B2 (en) Compositions and related methods for the treatment of cancer
US20240024491A1 (en) Mannosylated amine dextran drug delivery vehicles with degradable disulfide/carbonate linkers targeting payloads to cd206 expressing cells
US12006339B2 (en) CD206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker
US12404349B2 (en) Amide linkages of sugar moieties to amine terminated leashes attached to carbohydrate polymers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230814

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240611

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241203